Septerna Inc
NASDAQ:SEPN

Watchlist Manager
Septerna Inc Logo
Septerna Inc
NASDAQ:SEPN
Watchlist
Price: 28.23 USD -4.21% Market Closed
Market Cap: 1.3B USD

Operating Margin
Septerna Inc

-406%
Current
-6 493%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-406%
=
Operating Profit
-89.5m
/
Revenue
22m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Septerna Inc
NASDAQ:SEPN
1.3B USD
-406%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
496.3B USD
27%
CH
Roche Holding AG
SIX:ROG
262.9B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP
24%
CH
Novartis AG
SIX:NOVN
212.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
260.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
143B USD
29%
No Stocks Found

Septerna Inc
Glance View

Market Cap
1.3B USD
Industry
Pharmaceuticals

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. The company is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

SEPN Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-406%
=
Operating Profit
-89.5m
/
Revenue
22m
What is the Operating Margin of Septerna Inc?

Based on Septerna Inc's most recent financial statements, the company has Operating Margin of -406%.

Back to Top